Clinical Trial Update: to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of the Escherichia coli M17 probiotic for gastroesophageal reflux disease has completed. The update in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Escherichia coli M17 probiotic (Escherichia coli M17)

Snippet

Sponsor: BioBalance Corporation | Conditions: GERD | Phase 3 | Status: COMPLETED